Table 1.
Group | 2-OA–BSA | α-GalCer | IgM anti-PDC-E2† | IgG anti-PDC-E2† |
---|---|---|---|---|
CD8+/+ | – | – | 0·121 ± 0·006 | 0·024 ± 0·006 |
CD8+/+ | + | – | 0·622 ± 0·092 | 0·797 ± 0·105 |
CD8+/+ | + | + | 0·928 ± 0·105** | 1·136 ± 0·097** |
CD8−/− | – | – | 0·147 ± 0·016 | 0·029 ± 0·006 |
CD8−/− | + | – | 0·680 ± 0·064 | 0·736 ± 0·114 |
CD8−/− | + | + | 0·966 ± 0·095** | 1·126 ± 0·084** |
P < 0·05 compared to CD8−/− 2-octynoic acid conjugated bovine serum albumin (2-OA–BSA/PBS) controls.
O.D. ± s.e.m. α-GalCer = α-galactosylceramide; Ig = immunoglobulin; PDC-E2 = E2 subunits of the pyruvate dehydrogenase complex.